Genetic association between sexual maturity and weekly live-weights in laying-type Japanese quail

This study focused on the estimation of genetic relationships between weekly live weights and sexual maturity of male and female Japanese quail. The live body weight data of a laying-type quail line over time were collected from hatching to six weeks of age. Sexual maturity was determined as the day of production of cloacal gland foam for males, and the day of laying the first egg for females. (Co)Variance components and genetic parameters were estimated, using MTDFREML, a restricted maximum likelihood (REML) procedure using a model with direct and maternal genetic effects. Heritability estimates of weekly live weights ranged from moderate to high (0.20 - 0.60), and were higher for males than for females. The variance due to maternal effects disappeared gradually for males but rapidly for females as the chicks grew older. Heritability of age of sexual maturation was 0.24 ± 0.008 and 033 ± 0.136 for males and females, respectively. Genetic correlations between ages of reaching sexual maturity and live weights (except hatchling weight) were favourable for males (-0.16 to –0.45) and unfavourable for females (0.14 to 0.22). Genetic correlations between males and females ranged from moderate (0.46 ± 0.083) to high (0.98 ± 0.139) for weekly live weights, and were 0.71 ± 0.24 for age of reaching sexual maturity. Sexual size dimorphism can be explained by the differences in pattern of heritability and correlation estimates between reaching sexual maturity and live weights for males and females. South African Journal of Animal Science Vol. 36(2) 2006: 142-14

Management of spontaneous pneumothorax in patients with COVID-19.

ObjectivesThe coronavirus disease 2019 (COVID-19) pneumonia may cause cystic features of lung parenchyma which can resolve or progress to larger blebs. Pneumothorax was more likely in patients with neutrophilia, severe lung injury and a prolonged clinical course. The timely diagnosis and management will reduce COVID-19-associated morbidity and mortality.MethodsWe present 11 cases of spontaneous pneumothorax managed with chest tube thoracostomy or high-dose oxygen therapy. Isolated spontaneous pneumothorax was detected in all cases.ResultsEight cases were male and 3 cases were female. There were bilateral ground-glass opacities or pulmonary infiltrates in the parenchyma of the 10 cases. We detected neutrophilia, lymphopaenia and increased C-reactive protein, Ferritin, lactate dehydrogenase, D-Dimer, interleukin-6 levels in almost all cases. Chest tube thoracostomy was sufficient to treat pneumothorax in our 9 of case. In 2 cases, pneumothorax healed with high-dose oxygen therapy. Favipiravir and antibiotic treatment were given to different 10 patients. In our institution, all patients with COVID-19 infection were placed on prophylactic or therapeutic anticoagulation, unless contraindicated. The treatments of patients diagnosed with secondary spontaneous pneumothorax during the pandemic period and those diagnosed with secondary spontaneous pneumothorax in the previous 3 years were compared with the durations of tube thoracostomy performed in both groups.ConclusionsThe increased number of cases of pneumothorax suggests that pneumothorax may be a complication of COVID-19 infection. During medical treatment of COVID-19, pneumothorax may be the only reason for hospitalization. Although tube thoracostomy is a sufficient treatment option in most cases, clinicians should be aware of the difficulties that may arise in diagnosis and treatment

Tulathromycin disturbs blood oxidative and coagulation status

The aim of this study was to determine the effect of tulathromycin on serum oxidative status and coagulation factors in rabbits. Tulathromycin was administered to eight rabbits, and blood samples were obtained 0, 1, 5, 10 and 15 days after treatment. Indicators of serum oxidative status (malondialdehyde, nitric oxide, superoxide dismutase, retinol and -carotene) and coagulation values (antithrombin III, fibrinogen) were measured after tulathromycin treatment. In addition, routine serum biochemical values (creatine kinase-MB, lactate dehydrogenase, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, creatinine, blood urea nitrogen, cholesterol, triglyceride, high density lipoprotein, amylase, total protein, albumin, glucose and calcium), haemacell counts (white and red blood cells) and arterial blood gas parameters (packed cell volume, hemoglobin, pH, partial pressure of carbon dioxide, partial pressure of oxygen, actual bicarbonate, standard bicarbonate, total carbon dioxide, base excess in vivo, base excess in vitro, oxygen saturation, sodium and potassium) were also determined. Tulathromycin increased (P < 0.05) the levels of malondialdehyde, nitric oxide and superoxide dismutase activity, and decreased (P < 0.05) the level of antithrombin III. In conclusion, tulathromycin may cause oxidative damage and coagulation disorders during the treatment period.Key words: Tulathromycin, oxidative damage, coagulation disorder

Challenges, trends and approaches of future reliability engineering in high precision manufacturing processes

The progress within the development of manufacturing processes leads to complex failure modes and reliability problems within the product life cycle. This fact is valid in the case of mass production of consumer goods, e.g. automobiles, as well as small batch series of industrial goods, e.g. machine tools. Especially micro product platforms with a high amount of derivate and variants are challenging regarding to the planning of high precision manufacturing processes to ensure product reliability. This paper discusses challenges, trends and approaches of future reliability engineering in planning and realisation of high precision manufacturing processes. It considers e.g. mathematical models for uncertainty quantification, additive manufacturing, hydro micro forming, 3D printing and multivariate process validation models. The paper contains contributions of universities, institutes and original equipment manufacturers of industrial nations: Germany, United Kingdom, Japan, Turkey, Poland and U.S.A

Treatment of rabbit cheyletiellosis with selamectin or ivermectin: a retrospective case study

<p>Abstract</p> <p>Background</p> <p>A retrospective study of rabbits treated against cheyletiellosis was performed to evaluate the efficacy and safety of selamectin or ivermectin in clinical practice.</p> <p>Methods</p> <p>Medical records from 53 rabbits with microscopically confirmed <it>Cheyletiella </it>infestation were collected from two small animal clinics. The rabbits were divided into three groups, based on treatment protocols. Group 1 included 11 rabbits treated with ivermectin injections at 200–476 μg kg^-1subcutaneously 2–3 times, with a mean interval of 11 days. In Group 2, 27 rabbits were treated with a combination of subcutaneous ivermectin injections (range 618–2185 μgkg^-1) and oral ivermectin (range 616–2732 μgkg^-1) administered by the owners, 3–6 times at 10 days interval. The last group (Group 3) included 15 rabbits treated with selamectin spot-on applications of 6.2–20,0 mgkg^-1, 1–3 times with an interval of 2–4 weeks. Follow-up time was 4 months–4.5 years.</p> <p>Results</p> <p>Rabbits in remission were 9/11 (81,8%), 14/27 (51,9%) and 12/15 (80,8%) in groups 1, 2 and 3, respectively.</p> <p>Conclusion</p> <p>All treatment protocols seemed to be sufficiently effective and safe for practice use. Though very high doses were used in Group 2 (ivermectin injections followed by oral administration), the protocol seemed less efficacious compared to ivermectin injections (Group 1) and selamectin spot on (Group 3), respectively, although not statistically significant. Controlled prospective studies including larger groups are needed to further evaluate efficacy of the treatment protocols.</p